Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,190,248
  • Shares Outstanding, K 85,590
  • Annual Sales, $ 55,210 K
  • Annual Income, $ -109,750 K
  • 36-Month Beta N/A
  • Price/Sales 40.20
  • Price/Cash Flow N/A
  • Price/Book 11.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.44 +20.90%
on 06/11/18
26.91 -3.68%
on 06/19/18
+3.19 (+14.03%)
since 05/21/18
3-Month
17.74 +46.11%
on 05/08/18
33.75 -23.20%
on 03/22/18
-6.38 (-19.75%)
since 03/21/18
52-Week
8.10 +220.00%
on 07/14/17
33.99 -23.73%
on 03/21/18
+16.44 (+173.42%)
since 07/14/17

Most Recent Stories

More News
Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion...

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis

Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation ("Ambry"), a Konica Minolta company, today announced the launch of hATTR Compass(TM),...

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
Today's Free Research Reports Coverage on Agenus and Three More Biotech Stocks

Stock Research Monitor: AFMD, AKCA, and AKBA

AFMD : 1.73 (-6.76%)
AKCA : 25.92 (+1.29%)
Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Richard (Rich) A. Moscicki, M.D., to the Company's Board of Directors.

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

CAMBRIDGE, Mass. and CARLSBAD, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS),...

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that the Committee for Medicinal Products for Human Use...

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
New Research Coverage Highlights Cision Ltd., FCB Financial, Akcea Therapeutics, RE/MAX, Pain Therapeutics, and Regal Beloit -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cision Ltd. (NYSE:CISN), FCB...

RBC : 80.65 (-1.53%)
FCB : 60.25 (-2.51%)
RMAX : 54.90 (-0.90%)
PTIE : 9.28 (-2.01%)
AKCA : 25.92 (+1.29%)
CISN : 15.04 (-0.73%)
Wired News - FDA's Advisory Committee Supports Approval of Akcea's WAYLIVRA(TM) for Treatment of Familial Chylomicronemia Syndrome

Stock Monitor: Biofrontera Post Earnings Reporting

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
BFRA : 13.25 (+0.38%)
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration's (FDA) Division...

AKCA : 25.92 (+1.29%)
IONS : 42.17 (-4.22%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCA

Pomerantz LLP is investigating claims on behalf of investors of Akcea Therapeutics, Inc. ("Akcea" or the "Company") (NASDAQ: AKCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AKCA : 25.92 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 27.34
1st Resistance Point 26.46
Last Price 25.92
1st Support Level 24.86
2nd Support Level 24.14

See More

52-Week High 33.99
Last Price 25.92
Fibonacci 61.8% 24.10
Fibonacci 50% 21.04
Fibonacci 38.2% 17.99
52-Week Low 8.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar